Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.42 |
|---|---|
| 52-week range | $8.64 - $17.76 |
| 50-day moving average | $11.78 |
| 200-day moving average | $11.68 |
| Wall St. target price | $15.78 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.48 from 2025-05-22
| 1 week (2025-05-16) | -3.37% |
|---|---|
| 1 month (2025-04-25) | -18.98% |
| 3 months (2025-02-25) | -7.27% |
| 6 months (2024-11-25) | 3.89% |
| 1 year (2024-05-24) | -31.38% |
|---|---|
| 2 years (2023-05-24) | -46.23% |
| 3 years (2022-05-24) | 18.61 |
| 5 years (2020-05-21) | N/A |
Valuing Certara stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Certara's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Certara's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $98.1 million.
The EBITDA is a measure of a Certara's overall financial performance and is widely used to measure a its profitability.
To put Certara's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $394.5 million |
|---|---|
| Operating margin TTM | 7.19% |
| Gross profit TTM | $237.7 million |
| Return on assets TTM | 1.12% |
| Return on equity TTM | -0.25% |
| Profit margin | -0.67% |
| Book value | $6.72 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
We're not expecting Certara to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Certara's shares have ranged in value from as little as $8.635 up to $17.755. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Certara's is 1.572. This would suggest that Certara's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Certara's beta into context you can compare it against those of similar companies.
Certara, Inc. , together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
A deep dive into the highlights and limitations of Frec.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.